GeneOne 
Welcome,         Profile    Billing    Logout  
 7 Products   0 Diseases  7 Products   6 Trials   91 News 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INO-8000 / Inovio
NCT02419079: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Not yet recruiting
1/2
116
US
DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Placebo, placebo, placebo therapy, PLCB, sham therapy, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Chronic Hepatitis, Hepatitis C Infection
10/17
 
NCT02822079: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Recruiting
1
32
US
DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment
Mayo Clinic, Inovio Pharmaceuticals, National Cancer Institute (NCI)
Chronic Hepatitis, Hepatitis C Infection
03/20
 
NCT02772003: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Active, not recruiting
1
33
US
Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Rocakinogene Sifuplasmid, DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012
National Cancer Institute (NCI), Inovio Pharmaceuticals
Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma
03/20
03/26
zenuzolac (VGX-1027) / GeneOne
NCT04590547 / 2021-002730-16: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

Completed
2
132
Europe, US, RoW
GLS-1027, Placebo
GeneOne Life Science, Inc., GeneOne Life Science Inc.
Pneumonitis, SARS-CoV Infection
08/22
07/23
2021-002730-16: Safety, Tolerability, Efficacy and Dose Response of GLS-1027 in the Prevention of Sever Pneumonitis caused by COVID-19

Not yet recruiting
2
200
Europe
GLS-1027, GLS-1027, Capsule
GeneOne Life Science Inc., GeneOne Life Science Inc.
Patients with SARS-CoV-2 infection, Patients with COVID-19, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
quinine topical nasal spray (GLS-1200) / GeneOne, University of Pennsylvania
NCT04408183: GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

Terminated
2
184
US
GLS-1200, Placebo
GeneOne Life Science, Inc.
SARS-CoV 2, Infection
01/23
01/23
NCT04060316: GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery

Not yet recruiting
2
99
US
GLS-1200, Placebo, Sterile Saline
GeneOne Life Science, Inc.
Sinusitis Chronic
12/23
09/24
GLS-5310 / GeneOne
NCT04673149: GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)

Completed
1/2
183
RoW
GLS-5310, Placebo
GeneOne Life Science, Inc.
SARS-CoV-2
03/21
05/23
NCT05085639: GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)

Not yet recruiting
1
30
US
GLS-5130, Placebo
GeneOne Life Science, Inc.
Covid19, Healthy
04/22
12/22
NCT05182567: GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)

Active, not recruiting
1
69
US
GLS-5310 (Group 1), GLS-5310 (Group 2), GLS-5310 (Group 3), GLS-5310 (Group 4)
GeneOne Life Science, Inc.
COVID-19, Healthy
01/23
12/23
GLS-5100 / GeneOne, Korea Advanced Institute of Science and Technology
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INO-8000 / Inovio
NCT02419079: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Not yet recruiting
1/2
116
US
DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Placebo, placebo, placebo therapy, PLCB, sham therapy, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Chronic Hepatitis, Hepatitis C Infection
10/17
 
NCT02822079: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Recruiting
1
32
US
DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment
Mayo Clinic, Inovio Pharmaceuticals, National Cancer Institute (NCI)
Chronic Hepatitis, Hepatitis C Infection
03/20
 
NCT02772003: DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Active, not recruiting
1
33
US
Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Rocakinogene Sifuplasmid, DNA Plasmid Encoding Interleukin-12 INO-9012, INO-9012
National Cancer Institute (NCI), Inovio Pharmaceuticals
Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma
03/20
03/26
zenuzolac (VGX-1027) / GeneOne
NCT04590547 / 2021-002730-16: GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

Completed
2
132
Europe, US, RoW
GLS-1027, Placebo
GeneOne Life Science, Inc., GeneOne Life Science Inc.
Pneumonitis, SARS-CoV Infection
08/22
07/23
2021-002730-16: Safety, Tolerability, Efficacy and Dose Response of GLS-1027 in the Prevention of Sever Pneumonitis caused by COVID-19

Not yet recruiting
2
200
Europe
GLS-1027, GLS-1027, Capsule
GeneOne Life Science Inc., GeneOne Life Science Inc.
Patients with SARS-CoV-2 infection, Patients with COVID-19, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
quinine topical nasal spray (GLS-1200) / GeneOne, University of Pennsylvania
NCT04408183: GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

Terminated
2
184
US
GLS-1200, Placebo
GeneOne Life Science, Inc.
SARS-CoV 2, Infection
01/23
01/23
NCT04060316: GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery

Not yet recruiting
2
99
US
GLS-1200, Placebo, Sterile Saline
GeneOne Life Science, Inc.
Sinusitis Chronic
12/23
09/24
GLS-5310 / GeneOne
NCT04673149: GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)

Completed
1/2
183
RoW
GLS-5310, Placebo
GeneOne Life Science, Inc.
SARS-CoV-2
03/21
05/23
NCT05085639: GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)

Not yet recruiting
1
30
US
GLS-5130, Placebo
GeneOne Life Science, Inc.
Covid19, Healthy
04/22
12/22
NCT05182567: GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)

Active, not recruiting
1
69
US
GLS-5310 (Group 1), GLS-5310 (Group 2), GLS-5310 (Group 3), GLS-5310 (Group 4)
GeneOne Life Science, Inc.
COVID-19, Healthy
01/23
12/23
GLS-5100 / GeneOne, Korea Advanced Institute of Science and Technology
No trials found

Download Options